FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053581479> ?p ?o ?g. }

• W2053581479 endingPage "162" @default.
• W2053581479 startingPage "157" @default.
• W2053581479 abstract "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN). It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses.The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN.Data were pooled from 3 randomized, double-blind, placebo-controlled, parallel-group studies of gabapentin that focused on or included patients with PHN. Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24. The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo. Patients who were given higher doses of gabapentin had already received lower doses. An adverse event was recorded at the dose of its first onset and recorded again if its severity worsened at a higher dose.This study included data from 603 patients with PHN: 358 patients (196 [54.7%] women, 162 [45.3%] men; mean [SD] age, 72.3 [10.3] years) received gabapentin, and 245 (133 [54.3%] women, 112 [45.7%] men; mean [SD] age, 73.3 [10.7] years) received placebo. The 3 most common adverse events were dizziness, somnolence, and peripheral edema. Patients receiving gabapentin >or=1800 mg/d had a higher incidence of peripheral edema (7.5%) than those receiving gabapentin <1800 mg/d (1.4%) or placebo (1.6%) (P<0.002, gabapentin >or=1800 mg/d vs placebo). In contrast, the incidence of dizziness and somnolence was not higher in patients receiving gabapentin >or=1800 mg/d compared with those in the other groups. Compared with placebo recipients, patients receiving gabapentin <1800 mg/d reported a significantly greater frequency of dizziness (20.2% gabapentin <1800 mg/d vs 7.4% placebo; P<0.002) and somnolence (14.9% vs 5.8%, respectively; P=0.005). However, at >or=1800 mg/d, rates of dizziness (9.7%) and somnolence (6.9%) were comparable to those with placebo. Discontinuation rates were comparable between patients receiving gabapentin and those receiving placebo.In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d. Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d. Based on these findings, it does not appear that safety concerns should limit titration of gabapentin to achieve optimal efficacy." @default.
• W2053581479 created "2016-06-24" @default.
• W2053581479 creator A5042073172 @default.
• W2053581479 creator A5043773475 @default.
• W2053581479 creator A5059505571 @default.
• W2053581479 date "2004-09-01" @default.
• W2053581479 modified "2023-10-13" @default.
• W2053581479 title "Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia" @default.
• W2053581479 cites W1964941904 @default.
• W2053581479 cites W1966724162 @default.
• W2053581479 cites W1989667454 @default.
• W2053581479 cites W2031115386 @default.
• W2053581479 cites W2039982019 @default.
• W2053581479 cites W2055596822 @default.
• W2053581479 cites W2055967275 @default.
• W2053581479 cites W2057088834 @default.
• W2053581479 cites W2057983296 @default.
• W2053581479 cites W2078813321 @default.
• W2053581479 cites W2102023851 @default.
• W2053581479 cites W2102368782 @default.
• W2053581479 cites W2116876133 @default.
• W2053581479 cites W2117838151 @default.
• W2053581479 cites W2118649138 @default.
• W2053581479 cites W2139845603 @default.
• W2053581479 cites W2150883260 @default.
• W2053581479 cites W2322450883 @default.
• W2053581479 cites W33374171 @default.
• W2053581479 cites W4251922673 @default.
• W2053581479 cites W4376848786 @default.
• W2053581479 doi "https://doi.org/10.1016/j.amjopharm.2004.09.004" @default.
• W2053581479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15561647" @default.
• W2053581479 hasPublicationYear "2004" @default.
• W2053581479 type Work @default.
• W2053581479 sameAs 2053581479 @default.
• W2053581479 citedByCount "50" @default.
• W2053581479 countsByYear W20535814792012 @default.
• W2053581479 countsByYear W20535814792013 @default.
• W2053581479 countsByYear W20535814792014 @default.
• W2053581479 countsByYear W20535814792015 @default.
• W2053581479 countsByYear W20535814792016 @default.
• W2053581479 countsByYear W20535814792017 @default.
• W2053581479 countsByYear W20535814792018 @default.
• W2053581479 countsByYear W20535814792019 @default.
• W2053581479 countsByYear W20535814792020 @default.
• W2053581479 countsByYear W20535814792021 @default.
• W2053581479 countsByYear W20535814792022 @default.
• W2053581479 crossrefType "journal-article" @default.
• W2053581479 hasAuthorship W2053581479A5042073172 @default.
• W2053581479 hasAuthorship W2053581479A5043773475 @default.
• W2053581479 hasAuthorship W2053581479A5059505571 @default.
• W2053581479 hasConcept C126322002 @default.
• W2053581479 hasConcept C142724271 @default.
• W2053581479 hasConcept C168563851 @default.
• W2053581479 hasConcept C197934379 @default.
• W2053581479 hasConcept C204787440 @default.
• W2053581479 hasConcept C27081682 @default.
• W2053581479 hasConcept C2776608144 @default.
• W2053581479 hasConcept C2777107010 @default.
• W2053581479 hasConcept C2777482430 @default.
• W2053581479 hasConcept C2778866549 @default.
• W2053581479 hasConcept C2779034229 @default.
• W2053581479 hasConcept C42219234 @default.
• W2053581479 hasConcept C71924100 @default.
• W2053581479 hasConceptScore W2053581479C126322002 @default.
• W2053581479 hasConceptScore W2053581479C142724271 @default.
• W2053581479 hasConceptScore W2053581479C168563851 @default.
• W2053581479 hasConceptScore W2053581479C197934379 @default.
• W2053581479 hasConceptScore W2053581479C204787440 @default.
• W2053581479 hasConceptScore W2053581479C27081682 @default.
• W2053581479 hasConceptScore W2053581479C2776608144 @default.
• W2053581479 hasConceptScore W2053581479C2777107010 @default.
• W2053581479 hasConceptScore W2053581479C2777482430 @default.
• W2053581479 hasConceptScore W2053581479C2778866549 @default.
• W2053581479 hasConceptScore W2053581479C2779034229 @default.
• W2053581479 hasConceptScore W2053581479C42219234 @default.
• W2053581479 hasConceptScore W2053581479C71924100 @default.
• W2053581479 hasIssue "3" @default.
• W2053581479 hasLocation W20535814791 @default.
• W2053581479 hasLocation W20535814792 @default.
• W2053581479 hasOpenAccess W2053581479 @default.
• W2053581479 hasPrimaryLocation W20535814791 @default.
• W2053581479 hasRelatedWork W1972762029 @default.
• W2053581479 hasRelatedWork W1988457590 @default.
• W2053581479 hasRelatedWork W2010703163 @default.
• W2053581479 hasRelatedWork W2194911575 @default.
• W2053581479 hasRelatedWork W2330354427 @default.
• W2053581479 hasRelatedWork W2369524097 @default.
• W2053581479 hasRelatedWork W2376128908 @default.
• W2053581479 hasRelatedWork W2387522952 @default.
• W2053581479 hasRelatedWork W2919765778 @default.
• W2053581479 hasRelatedWork W4244043415 @default.
• W2053581479 hasVolume "2" @default.
• W2053581479 isParatext "false" @default.
• W2053581479 isRetracted "false" @default.
• W2053581479 magId "2053581479" @default.
• W2053581479 workType "article" @default.